Data from syngeneic mouse models demonstrated that dual LAG-3/PD-1 blockade reduced tumor growth by increasing the proportion of effector T cells in the tumor.12 A number of LAG-3–targeting molecules are currently in early stages of clinical development, with early results suggesting a modest benefit of single-agent, anti-LAG-3 treatment, supporting the potential of combination approaches.13 This evidence concerns the gene LAG3 and neoplasm.